Dr. Reddy’s Laboratories Limited (NYSE: RDY) has introduced the Fluphenazine Hydrochloride Tablets, USP is US markets. The tablets are authorized by FDA. Dr. Reddy’s disclosed that the Fluphenazine Hydrochloride Tablets, USP are offered in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
As per the IQVIA Health, the Prolixin brand and generic had U.S. sales of nearly $134 million MAT for the very latest 12-month period completed in December 2020. Yesterday, Dr. Reddy Laboratories has introduced Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets. These tablets are also authorized by the U.S. FDA.
Dr. Reddy’s Laboratories Limited (NYSE: RDY) shares dropped 2.14% on Wednesday at the time of writing. In the past 52-weeks of trading, this firm's wavered $33.33 to $73.50 in the past 52-weeks of low and high range, respectively. Its shares increased 87.97% from its 52-week low and dropped -14.76% from its 52-week high.
Seeing its profitability, it as return on investment is 6.40%, ROE is 9.70%, and ROA is 6.40%. RDY has Gross Margin, Profit Margin, and Operating Margin of 53.90%, 8.50%, and 9.50%, respectively. Focusing on its liquidity, its current ratio stood at 1.70 and a quick ratio stood at 1.20. Dr. Reddy’s Laboratories Limited's market cap has remained high, reaching $10.46 billion at the time of writing.
According to IQVIA Health, the Xeloda brand and generic had U.S. sales of nearly $90 million MAT for the very latest 12- months period completed in October 2020. These tablets are offered by the firm in 150 mg and 500 mg powers in bottle count sizes of 60 and 120, individually.